Verastem Oncology (NASDAQ: VSTM) has announced the discontinuation of the ramp 203 phase 1/2 clinical trial for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) in order to focus resources on the clinical development of VS-7375, an oral KRAS G12D (on/off) inhibitor, in advanced NSCLC and other solid tumors.
As of the data cutoff on November 26, 2025, the following results were reported from the ramp 203 clinical trial:
- For the doublet combination of avutometinib and lumakras™ (sotorasib) in G12C-inhibitor treatment-naïve patients, an overall response rate (ORR) of 40% (12/30) was achieved, with a median progression-free survival (MPFS) of 11.1 months.
- In the previously G12C-inhibitor treated group for the doublet combination, an ORR of 9.5% (2/21) and a MPFS of 3.7 months were reported.
- Among the triple combination of avutometinib, lumakras™, and defactinib, a 50% ORR (2/4) was achieved in G12C-inhibitor treatment-naïve patients, with one patient showing a best response of stable disease (SD).
- In the triplet combination for patients previously treated with a KRAS G12C inhibitor, 36% showed greater than 30% tumor reduction, with a median PFS of 3.6 months.
Across the doublet and triplet combinations evaluated, no dose-limiting toxicities were observed, and treatment-related adverse events were generally manageable, with nausea (56.8%), diarrhea (52.7%), and fatigue (45.9%) being the most common.
The company expressed its gratitude to the investigators, patients, and families who participated in the program and mentioned that they are assessing opportunities to share the data in the future.
Verastem Oncology is currently evaluating the combination of avutometinib and defactinib in other cancer types, including low-grade serous ovarian cancer and metastatic pancreatic cancer.
Avutometinib, which inhibits MEK kinase activity, and defactinib, a FAK inhibitor, were approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer on May 8, 2025. The company is also conducting a phase 3 confirmatory trial for this indication and evaluating the combination with standard-of-care chemotherapy as a potential treatment in the first line for patients with advanced pancreatic cancer.
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing new medicines for patients diagnosed with RAS/MAPK pathway-driven cancers.
Verastem's stock is listed on the NASDAQ under the ticker symbol VSTM. Today the company's shares have moved 2.13% to a price of $7.915. If you want to know more, read the company's complete 8-K report here.
